Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.84 |
| ▸ | PKM | P14618 | 3/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8200020 | 1.00 | KMT2A (0.84) | KMT2APKMHTTPOLBALDH1A1 | |
| SCHEMBL9386579 | 1.00 | KMT2A (0.84) | KMT2APKMHTTPOLBALDH1A1 | |
| SCHEMBL8205136 | 0.95 | KMT2A (0.94) | KMT2APKMHTTPOLBALDH1A1 | |
| SCHEMBL17194214 | 0.95 | KMT2A (0.77) | KMT2APKMHTTPOLBALDH1A1 | |
| SCHEMBL17084934 | 0.93 | KMT2A (0.97) | KMT2APKMHTTPOLBALDH1A1 | |
| SCHEMBL10724066 | 0.92 | PKM (0.88) | KMT2APKMHTTPOLBALDH1A1 | |
| SCHEMBL699639 | 0.92 | PKM (0.88) | KMT2APKMHTTPOLBALDH1A1 | |
| SCHEMBL565301 | 0.92 | PKM (0.88) | KMT2APKMHTTPOLBALDH1A1 | |
| SCHEMBL4537086 | 0.92 | PKM (0.88) | KMT2APKMHTTPOLBALDH1A1 | |
| SCHEMBL8203532 | 0.92 | PKM (0.88) | KMT2APKMHTTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0104353-B1 | HEAT SENSITIVE RECORD MATERIAL | HODOGAYA CHEMICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | claimed |
| US-4482905-A | FLUORAN, BENZENESULFONAMIDE, ACID, BINDER | HODOGAYA CHEMICAL CO., LTD. (JP) | 1984-11-13 | — | — | US | claimed |
| EP-0104353-A2 | Heat sensitive record material | HODOGAYA CHEMICAL CO., LTD. (JP) | 1984-04-04 | — | — | EP | claimed |
| WO-2024026433-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023287793-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-3440084-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022135365-A1 | DISUBSTITUTED CYCLOPENTANE KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022111621-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-02 | — | — | WO | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| EP-3738964-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7220529-B2 | Photopolymerizable composition and recording material using the same | FUJIFILM CORPORATION (JP) | 2007-05-22 | — | — | US | disclosed |
| WO-2002078970-A1 | HEAT SENSITIVE RECORDING MATERIAL | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-10-10 | — | — | WO | disclosed |
| EP-0624584-B1 | Piperazine derivatives useful as calmodulin inhibitors | DAIICHI SEIYAKU CO (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5681954-A | HAS CALMODULIN INHIBITORY ACTIVITY; USEFUL IN TREATING DISEASES OF THE CIRCULATORY ORGANS OR IN CEREBRAL REGION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | disclosed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | KMT2A 1998/4885PKM 3736/4885HTT 1546/4885 |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | HTR2C, HTR2A, HTR1A | KMT2A 3553/4885PKM 4039/4885HTT 1213/4885 |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | HSPBP1, HSPA8, HSPH1 | KMT2A 3385/4885PKM 3307/4885HTT 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.